Pulmonary fibrosis is a chronic, progressive interstitial lung disease that severely affects respiratory function and can lead to death due

 to complications such as acute respiratory failure, acute coronary syndrome, congestive heart failure, lung cancer, infections, and 

venous thrombosis. It is estimated that there are approximately 3.4 million patients with pulmonary fibrosis in China, with about 

100,000 new cases diagnosed each year. The median survival time for patients with idiopathic pulmonary fibrosis (IPF) is 2-3 years, 

and the five-year survival rate is below 30%, which is lower than that of most cancers, leading to it being referred to as "the cancer

 that is not cancer."

Recently, the internationally renowned translational medicine journal *Bioengineering & Translational Medicine* (JCR Q1, IF=10.684) 

published an article titled "Macrophage-based delivery of anti-fibrotic proteins alleviates bleomycin-induced pulmonary fibrosis in 

mice." This project was a collaborative effort involving RocRock Biotech, the General Hospital of the People's Liberation Army, Shenyang

 University of Chemical Technology, and Shenzhen University General Hospital. Utilizing Kunshi Biotech's Del-M technology platform, 

the study demonstrated the application of an engineered macrophage-based protein delivery system in treating a mouse model of

 pulmonary fibrosis induced by bleomycin, showing promising therapeutic effects. RocRock Biotech is the corresponding author of this 

paper, with Dr. Yin Xiushan, the founder and CEO of RocRock Biotech, serving as the corresponding author. The publication of these 

research results reflects the deep expertise of Kunshi's R&D team in the field of engineered macrophage development, enriches 

RocRock Biotech's pipeline for engineered macrophages, and showcases the promising translational prospects of the Del-M 

technology platform in the realm of chronic disease cell therapy.